TY - JOUR T1 - Six months outcomes from patients treated with lung volume reduction coils in a commercial setting: The RKK Stuttgart experience JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P2292 AU - Martin Hetzel AU - Tobias Merk AU - Andrea Philipp AU - Stefan Veitshans AU - Peter Willmes Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P2292.abstract N2 - Introduction: Since 2010, endoscopic lung volume reduction in patients with pulmonary emphysema using RePneu LVR-coils (LVRC) is an approved treatment approach in Germany. The method has been demonstrated to be safe and efficacious in European multi-center studies.Objectives: LVRC has been considered part of the routine clinical care for selected emphysema patients at RKK Stuttgart since 2011. A validated analysis of patient outcomes is presented here.Methods: Analysis was conducted on all bilaterally treated patients with at least one follow up visit (N=29, mean 165 days post baseline) after the second treatment (lung function tests, 6MWT, and complications). Selection criteria included patients with homogeneous or heterogeneous emphysema and RV >200% pred. Exclusion criteria included severe pulmonary hypertension, anticoagulant therapy, and bronchiectasis.Results: The mean changes from baseline were: RV -1.39L, FEV1 +80.0mL, 6MWT +94.0m. Following 29 bilateral treatments (58 total procedures), we observed the following severe complications through the 6 month follow-up visit: COPD Exacerbation (6), Hemoptysis >5 mL (3), Pneumonia (1), Chest Pain (1), Aspiration (1), Embolus of lung artery (1). Additional data including follow-up at 9-months and 12-months will be collected and reported.Conclusion: LVRC results in significant improvement of lung function and an increase in physical performance of treated patients. The procedure is well tolerated with an acceptable safety profile. ER -